MedElevator Войти в исследования
← Поиск публикаций

DOI 10.23736/s2784-8671.22.07224-3

Медицинская библиотека · Italian journal of dermatology and venereology · 2022

Biosimilar versus originator etanercept: a real-life clinical study.

Giordano Domenico, Capalbo Alessandro, Gagliostro Nazareno, Fedele Giusy, Balampanos Charalampos G, Persechino Flavia, Bushati Vilma, Ulisse Salvatore, Persechino Severino, Pellacani Giovanni

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Over the last few years, novel therapeutic approaches based on the use of monoclonal antibodies against cytokines, or their cognate receptors, involved in psoriasis progression have shown remarkable results, being capable to reduce disease progression and increase patient's quality of life. Among these is etanercept (Enbrel®, Pfizer, Sandwich, UK) and its biosimilar compound SB4 (Benepali®, Samsung Bioepis, Delft, The Netherlands), both approved for the treatment of moderate to severe psoriasis. Aim of the present study was to evaluate in a less controlled environment, such as real-life, the actual bioequivalence between the etanercept (ETN) and the SB4 in term of safety, efficacy and patient's quality of life.

METHODS

For this purpose, we analyzed a case study consisting of 65 patients affected by plaque psoriasis, with or without psoriatic arthritis at our dermatological outpatient center of Sant'Andrea Hospital in Rome, all of them under treatment with either ETN or the biosimilar SB4 drug for at least 3 months. The indicators used to evaluate the effectiveness of the therapies were the Psoriasis Area and Severity Index, the Visual Analogue Scale (VAS) for itch, the VAS for pain, and the Dermatology Life Quality Index.

RESULTS

The results showed no significant differences among the two drugs in all the analyzed parameters confirming the equivalence between the ETN and its biosimilar SB4.

CONCLUSIONS

Overall, we can confirm the overlapping clinical efficacy between ETN and its biosimilar SB4 drug and that even in an uncontrolled environment such as real-life, the biosimilar drugs are an excellent opportunity to reduce health costs allowing to expand the audience of patients who can benefit from these innovative treatments.

Для цитирования: Giordano Domenico, Capalbo Alessandro, Gagliostro Nazareno, Fedele Giusy, Balampanos Charalampos G, Persechino Flavia, Bushati Vilma, Ulisse Salvatore, Persechino Severino, Pellacani Giovanni. Biosimilar versus originator etanercept: a real-life clinical study.. Italian journal of dermatology and venereology. 2022. DOI: 10.23736/s2784-8671.22.07224-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.